Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

Ruxolitinib can help regrow hair in severe alopecia areata.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

ZD1839 can cause skin issues like acne and hair changes.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Glibenclamide slows breast cancer cell growth by stopping cell division.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.